Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 5, 1998, Pages 281-285

  Carney, Michael E ^a   Maxwell, G Larry ^a   Lancaster, Johnathan M ^a   Gumbs, Curtis ^a   Marks, Jeffrey ^a   Berchuck, Andrew ^a   Futreal, P Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Ovarian cancer; TSG101; Tumor suppressor gene

Indexed keywords

GENE PRODUCT; TUMOR SUPPRESSOR GENE PROTEIN TSG 101; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BREAST NEOPLASMS; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HUMANS; LEUCINE ZIPPERS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 0031754147     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(98)00018-5     Document Type: Article

References (23)

1. Berchuck A., Carney M., Lancaster J.M., Marks J., Futreal P.A. Familial breast-ovarian cancer syndromes BRCA1 and BRCA2 . Clin Obstet Gynecol. 41:1998;157-166.
2. Berchuck A., Elbendary A., Havrilesky L., Rodriguez G.C., Bast R.C. Pathogenesis of ovarian cancers. J Soc Gynecol Invest. 1:1994;181-190.
3. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
4. Casey G., Lopez M.E., Ramos J.C., et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
5. Li L., Li X., Francke U., Cohen S.N. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell. 88:1997;143-154.
6. Li L., Cohen S.N. TSG101 A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells . Cell. 85:1996;319-329.
7. Koonin E.V., Abagyan R.A. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nature Genet. 16:1997;330-331.
8. Koi M., Johnson L.A., Kalikin L.M., Little P.F.R., Nakamura Y., Feinberg A.P. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from human chromosome 11. Science. 260:1993;361-364.
9. Tran Y.K., Newsham I.F. High density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res. 56:1996;2916-2921.
10. Winqvist R., Hampton G.M., Mannermaa A., et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res. 55:1995;2660-2664.
11. Weitzel J.N., Patel J., Smith D.M., Goodman A., Safaii H., Ball H.G. Molecular genetic changes associated with ovarian cancer. Gynecol Oncol. 55:1994;245-252.
12. Zheng J., Wan M., Zweizig S., Velicescu M., Yu M.C., Dubeau L. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res. 53:1993;4138-4142.
13. Vandamme B., Lissens W., Amfo K., et al. Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res. 52:1992;6646-6652.
14. Kiechele-Schwarz M., Bauknecht T., Wienker T., Walz L., Pfleiderer A. Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Cancer. 72:1993;2423-2432.
15. Maxwell P.L., Feinberg A.P. Aberrant splicing but no mutations of TSG101 in human breast cancer. Cancer Res. 57:1997;3131-3134.
16. Steiner P., Barnes D.M., Harris W.H., Weinberg R.A. Absence of rearrangements in the tumor susceptibility gene TSG101 in human breast cancer. Nature Genet. 16:1997;332-333.
17. Vaughn J.P., Cirisano F.D., Huper G., et al. Cell cycle control of BRCA2. Cancer Res. 56:1996;4590-4594.
18. Ilekis J.V., Garutu J., Niederberger C., Sciccia B. Expression of a truncated EGF receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol. 65:1997;36-41.
19. Cannistra S.A., Abu-Jawdeh G., Niloff J., et al. CD44 variant expression is a common feature of epithelial ovarian cancer Lack of association with standard prognostic factors . J Clin Oncol. 13:1995;1912-1921.
20. Murphy L.C. Estrogen receptor variants in human breast cancer. Mol Cell Endocrinol. 74:1990;C83-C86.
21. Lu M., Conzen S.D., Cole C.N., Arrick B.A. Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res. 56:1997;4578-4581.
22. Thakur S., Zhang H.B., Peng Y., et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol. 17:1997;444-452.
23. Wilson C.A., Payton M.N., Elliott G.S., et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-11b. Oncogene. 14:1997;1-16.